Clay Siegal: Paving a Path in Cancer Treatment Therapies

As an entrepreneur Clay Siegal could not have had better motivation. His father suffered from cancer for years while Siegal as a young man looked on. Nobody wants to see a loved one eaten alive by a debilitating health issue. It was incredibly sad and frustrating when there were very limited drug therapy options available to his father. He made it his goal to improve options for cancer patients and create more effective medications and treatments. Siegal co-founded Seattle Genetics knowing that learning never stops and as he got older he only found out that he knew so little in the grand scheme of life. Siegal turned his family’s terrible loss into a goal for both his career and life.

Seattle Genetics was co-founded by Dr. Clay Siegall after he began a gaining valuable experience and experience. He graduated from the University of Maryland with a B.S. in zoology followed by earning his Ph.D. in genetics from George Washington University. After securing his education Siegall spent many years as a research scientist at the National Cancer Institute, National Institutes of Health, and the Bristol-Myers Squibb Pharmaceutical Research Institute. He serves on three medical related boards, has had 70 research projects published, and holds a whopping 15 patents.

Clay Siegall is the President of Seattle Genetics. They are a biotechnology company that works to create new solutions to cancer-treating therapies. Their biggest success was the development of the drug ADCETRIS, an antidrug conjugate. Since their initial success, Siegall has led the way to further success with a focus on research, innovation, and clinical trials. ADCETRIS has been approved for use all across the world and continues to get additional patents and clearances. Seattle Genetics partnered up with Takeda Pharmaceutical Company to further expand their resources and spread the drug availability internationally. Siegall takes his success in stride and remembers that his focus and the company’s focus is on the patients.